References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30
- Howlander N, Noone AM, Krapcho M, et al. SEER Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute; 2016
- NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) Version 2.2017. 2016. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed June 5, 2017
- Yu B, Tiwari RC, Cronin KA, et al. Cure fraction estimation from the mixture cure models for grouped survival data. Stat Med 2004;23:1733-47
- Bradley CJ, Yabroff KR, Mariotto AB, et al. Antineoplastic treatment of advanced-stage non-small-cell lung cancer: treatment, survival, and spending (2000 to 2011). J Clin Oncol 2017;35:529-35
- Henk HJ, Ray S. Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer. Lung Cancer Manag 2013;2:189-97
- Hess LM, Rajan N, Winfree K, et al. Cost Analyses in the US and Japan: a cross-country comparative analysis applied to the PRONOUNCE trial in non-squamous non-small cell lung cancer. Adv Ther 2015;32:1248-62
- Hess LM, Cinfio FN, Wetmore S, et al. Enhancing the budget impact model for institutional use: a tool with practical applications for the hospital oncology pharmacy. Hosp Pharm 2016;51:452-60
- Ting J, Tien Ho P, Xiang P, et al. Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health J Int Soc Pharmacoecon Outcomes Res 2015;18:774-82
- Kumar G, Woods B, Hess LM, et al. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer 2015;89:294-300
- Markman M, Luce R. Impact of the cost of cancer treatment: an internet-based survey. J Oncol Pract Am Soc Clin Oncol 2010;6:69-73
- ACS-CAN. ACS CAN examination of cancer drug coverage and transparency in the health insurance marketplaces. ACS-CAN; 2015. https://www.acscan.org/policy-resources/acs-can-examination-cancer-drug-coverage-and-transparency-health-insurance. Accessed June 5, 2017
- Appleby J. Cancer meds often bring big out-of-pocket costs for patients, report finds. Kaiser Health News 2015 http://khn.org/news/cancer-meds-often-bring-big-out-of-pocket-costs-for-patients-report-finds/ Accessed June 5, 2017
- Marsa L. The high cost of cancer care: Your money or your life? Newsweek 2015. http://www.newsweek.com/2015/07/31/high-cost-cancer-care-your-money-or-your-life-356369.html. Accessed June 5, 2017
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
- Johnson CY. The burden of cancer isn't just cancer. The Washington Post [Internet]. 2016. www.washingtonpost.com/news/wonk/wp/2016/04/08/cancers-sinister-side-effect-financial-toxicity. Accessed September 29, 2016
- DeLuna R. Seattle woman experiences financial devastation following cancer diagnosis. KUOWORG [Internet]. 2015. kuow.org/post/seattle-woman-experiences-financial-devastation-following-cancer-diagnosis. Accessed September 29, 2016
- Kullgren JT, Galbraith AA, Hinrichsen VL, et al. Health care use and decision making among lower-income families in high-deductible health plans. Arch Intern Med 2010;170:1918-25